Article Text

Download PDFPDF

Clinical course and outcome of COVID-19 in patients with rheumatic diseases: are all biological disease-modifying antirheumatic drugs alike? Response to: ‘Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab’ by Schulze-Koops et al
  1. Sara Monti1,2,
  2. Carlomaurizio Montecucco1
  1. 1 Rheumatology, Fondazione IRCCS Policlinico San Matteo, Pavia, Lombardia, Italy
  2. 2 PhD in Experimental Medicine, University of Pavia, Pavia, Lombardia, Italy
  1. Correspondence to Dr Sara Monti, Rheumatology, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy; sara.saramonti{at}

Statistics from

We appreciated the comment from Schulze-Koops et al 1 in response to our paper on the clinical course and outcome of COVID-19 in a cohort of patients treated with biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs).2 The authors stated that the message conveyed by our report or other similar observational data or clinical studies is potentially harmful for patients with rheumatic diseases who might think they are protected against complications of COVID-19 by their immunomodulatory drug. Nevertheless, in our publication, we clearly stated that our findings did not allow any conclusions on the overall outcome of immunocompromised patients affected by COVID-19 and that a high level of vigilance and strict follow-up should be maintained on these susceptible patients. Moreover, our findings …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles